The effects of antihypertensive drugs on serum lipids and lipoproteins, I. Diuretics
- PMID: 3530704
- DOI: 10.2165/00003495-198632030-00003
The effects of antihypertensive drugs on serum lipids and lipoproteins, I. Diuretics
Abstract
Potassium-losing diuretic drugs, when used in the treatment of hypertension, cause unfavourable short term alterations in blood lipid and lipoprotein concentrations. The disturbance is characterised by increases in total cholesterol of 4 to 13%, in low density lipoprotein (LDL) cholesterol of 7 to 29%, in very-low density lipoprotein (VLDL) cholesterol of 7 to 56%, and in total triglyceride of 14 to 37%. The disturbance is variable among patients and over time in individual patients; it is absent in some. In long term treatment the data are fragmentary, but total cholesterol and triglycerides usually return to baseline values or below. The variability of the lipid response to diuretics has several consequences: firstly, it necessitates a sizeable study population (minimum of 30 patients) in order to document convincingly its presence or absence; secondly, lipoprotein fractions must be examined to define the pattern of the disturbance; and thirdly, the subsidence of the diuretic-induced lipid effects in long term treatment may be more apparent than real because even larger decreases have been noted in untreated groups in the few studies that wisely included these important controls for comparison. While the cause of the lipid-lipoprotein aberration is unclear, existing data suggest that certain attributes of the study population influence the response, i.e. age, habitual diet, hormonal milieu (gender), baseline cholesterol concentrations, and induced glucose intolerance. The apparent absence of lipid alterations with indapamide needs to be substantiated and compared with low doses of a standard thiazide-type drug. The lipid-lipoprotein effects of diuretics seem inconsequentially small, but they may contribute to the disappointing failure of diuretic-based regimens to lower the incidence of coronary heart disease in hypertensive patients. Nevertheless, diuretic-based treatment remains the only therapeutic regimen of proven benefit to congestive heart failure in patients with hypertension, and it is superior to beta-blockade in preventing stroke. Hence, alternative antihypertensive drug regimens must be compared prospectively with diuretics in order to verify any theoretic superiority.
Similar articles
-
The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs.Drugs. 1986 Oct;32(4):335-57. doi: 10.2165/00003495-198632040-00003. Drugs. 1986. PMID: 2877846 Review.
-
[Antihypertensive therapy and lipid metabolism].Klin Wochenschr. 1984 Mar 1;62(5):193-202. doi: 10.1007/BF01721044. Klin Wochenschr. 1984. PMID: 6143851 Review. German.
-
The influence of non-beta-blocking drugs on the lipid profile: are diuretics outclassed as initial therapy for hypertension?Am Heart J. 1987 Oct;114(4 Pt 2):998-1006. doi: 10.1016/0002-8703(87)90599-0. Am Heart J. 1987. PMID: 2889346 Review.
-
Effects of diuretic drugs on the lipid profile.Drugs. 1988;36 Suppl 2:33-40. doi: 10.2165/00003495-198800362-00007. Drugs. 1988. PMID: 3063504 Review.
-
Effect of diuretics on the plasma lipid profile.Eur Heart J. 1992 Dec;13 Suppl G:61-7. doi: 10.1093/eurheartj/13.suppl_g.61. Eur Heart J. 1992. PMID: 1486908 Review.
Cited by
-
Effects of acebutolol on the serum lipid profile.Drugs. 1988;36 Suppl 2:41-50. doi: 10.2165/00003495-198800362-00008. Drugs. 1988. PMID: 3063505 Review.
-
Comparison of the efficacy and safety of once-daily versus twice-daily formulations of diltiazem in the treatment of systemic hypertension. The Canadian Multicenter Diltiazem-CD Hypertension Trial Group.Cardiovasc Drugs Ther. 1995 Jun;9(3):413-20. doi: 10.1007/BF00879030. Cardiovasc Drugs Ther. 1995. PMID: 8527351 Clinical Trial.
-
Frusemide causes acute increases in lipid concentrations.Br J Clin Pharmacol. 1993 Dec;36(6):607-9. doi: 10.1111/j.1365-2125.1993.tb00423.x. Br J Clin Pharmacol. 1993. PMID: 12959281 Free PMC article. Clinical Trial.
-
Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.Drugs. 1988 May;35(5):525-41. doi: 10.2165/00003495-198835050-00003. Drugs. 1988. PMID: 2899495 Review.
-
The Effect of Tolvaptan on Metabolism and Electrolyte Homeostasis in Patients with Heart Failure: A Systematic Review and Meta-Analysis.Rev Cardiovasc Med. 2024 Sep 19;25(9):334. doi: 10.31083/j.rcm2509334. eCollection 2024 Sep. Rev Cardiovasc Med. 2024. PMID: 39355601 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical